Lloyd Price
- Jun 22, 2023

Doctolib to IPO in 2024? Europe's first $10Bn public HealthTech company?

Exec Summary:

There is no official announcement yet about Doctolib's IPO date. However, there have been reports that the company is considering an IPO in 2024.

In March 2022, Doctolib raised $549 million in a funding round that valued the company at $6.4 billion. This funding round was led by Eurazeo and Bpifrance, and it was seen as a sign that Doctolib is preparing for an IPO.

Doctolib is a leading digital healthcare platform in Europe, and it has seen rapid growth in recent years. The company has over 60 million users in France, Germany, and Italy, and it is expanding into new markets.

If Doctolib does IPO in 2024, it is likely to be one of the most anticipated IPOs of the year. The company is well-positioned for growth, and it has a strong track record of innovation.

Here are some factors that could affect Doctolib's IPO date:

The overall market conditions. The IPO market is cyclical, and it is possible that the market conditions will not be favorable for an IPO in 2023 or 2024.
The regulatory environment. The regulatory environment for digital healthcare is still evolving, and it is possible that there will be new regulations that could affect Doctolib's IPO.
The company's own financial performance. Doctolib's financial performance will need to be strong in order to attract investors in an IPO.

Overall, it is too early to say for sure when Doctolib will IPO. However, the company is well-positioned for growth, and it is likely to be one of the most anticipated IPOs of the year if it does go public in the next few years.

Growth and M&A for Healthcare Technology companies

Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit https://www.healthcare.digital

HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Email lloyd@nelsonadvisors.co.uk

HealthTech M&A Newsletter from Nelson Advisors - HealthTech, Health IT, Digital Health Insights and Analysis. Subscribe Today! https://lnkd.in/e5hTp_xb

HealthTech Corporate Development and M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. Visit www.nelsonadvisors.co.uk

#HealthTech #HealthIT #DigitalHealth #lloydgprice #NelsonAdvisors

History of Doctolib:

Doctolib was founded in 2013 by Stanislas Niox-Chateau, Jessy Bernal, Ivan Schneider, and Steve Abou-Rjeily. The company's mission is to make healthcare more accessible and efficient for patients and healthcare professionals.

Doctolib started as a scheduling platform for doctors, but it has since expanded to offer a variety of other services, including:

Telemedicine: Patients can schedule video or phone appointments with their doctors.
Messaging: Patients can use Doctolib to message their doctors between appointments.
Back-office management: Healthcare staff can manage their patient records, billing, and scheduling.

Doctolib has seen rapid growth in recent years. The company now has over 60 million users in France, Germany, and Italy, and it is expanding into new markets.

In March 2022, Doctolib raised $549 million in a funding round that valued the company at $6.4 billion. This funding round was led by Eurazeo and BPIFrance, and it was seen as a sign that Doctolib is preparing for an IPO.

Doctolib is a leading digital healthcare platform in Europe, and it is well-positioned for growth. The company is committed to making healthcare more accessible and efficient for patients and healthcare professionals, and it is likely to continue to grow in the years to come.

Here are some of the key milestones in Doctolib's history:

2013: Doctolib is founded in Paris, France.
2014: Doctolib launches in Germany.
2016: Doctolib launches in Italy.
2017: Doctolib raises €100 million in Series C funding.
2018: Doctolib launches its telemedicine platform.
2019: Doctolib raises €150 million in Series D funding.
2020: Doctolib launches its messaging platform.
2021: Doctolib raises €250 million in Series E funding.
2022: Doctolib raises $549 million in Series F funding.

Doctolib is a rapidly growing company with a bright future. The company is well-positioned to continue to grow in the years to come, and it is likely to play a key role in the digital transformation of healthcare.

What could a Doctolib IPO in 2024 look like?

A Doctolib IPO in 2024 could look like a number of different things, but here are some possible scenarios:

The company could go public at a valuation of $10 billion or more. Doctolib is a leading digital healthcare platform in Europe, and it has seen rapid growth in recent years. The company has over 60 million users in France, Germany, and Italy, and it is expanding into new markets. If Doctolib goes public in 2024, it is likely to be valued at a high price.
The company could raise $1 billion or more in its IPO. Doctolib would need to raise a significant amount of money in its IPO in order to fund its growth plans. The company is expanding into new markets, and it is investing in new technologies. An IPO would provide Doctolib with the capital it needs to continue its growth.
The company could list on the Euronext Paris stock exchange. Doctolib is a French company, so it is likely to list on the Euronext Paris stock exchange. The Euronext Paris is a leading stock exchange in Europe, and it would provide Doctolib with access to a large pool of investors.

Of course, these are just a few possible scenarios. The actual outcome of a Doctolib IPO in 2024 will depend on a number of factors, including the overall market conditions and the company's financial performance.

However, it is clear that Doctolib is a high-growth company with a bright future, and an IPO in 2024 would be a major milestone for the company.

Does Doctolib need to launch in the UK before an IPO?

Doctolib does not need to launch in the UK before an IPO. However, it would be a strategic move for the company to do so, as the UK is a large and growing market for digital health. Doctolib already has a presence in France and Germany, and launching in the UK would give the company a foothold in one of the most important markets in Europe.

There are a number of factors that Doctolib would need to consider before launching in the UK. These include the regulatory environment, the competitive landscape, and the patient demand for digital health services. However, if Doctolib can successfully navigate these challenges, launching in the UK could be a major boost for the company's IPO.

According to a recent report by Grand View Research, the global digital health market is expected to reach $498.6 billion by 2027. The UK is a major driver of this growth, and the country is expected to account for 4.8% of the global market by 2027.

Doctolib is well-positioned to capitalize on this growth. The company has a strong track record in France and Germany, and it has a proven technology platform. If Doctolib can successfully launch in the UK, it could become a major player in the global digital health market.

Here are some of the benefits that Doctolib could reap from launching in the UK:

Increased market share: The UK is a large and growing market for digital health, and Doctolib could gain a significant share of this market by launching in the country.
Increased revenue: Doctolib could generate more revenue from the UK market, which would help to boost the company's valuation ahead of its IPO.
Increased brand awareness: Launching in the UK would help to raise Doctolib's profile and brand awareness, which would be beneficial for the company's IPO.

Of course, there are also some risks associated with launching in the UK. These include the regulatory environment, the competitive landscape, and the patient demand for digital health services. However, if Doctolib can successfully navigate these challenges, launching in the UK could be a major boost for the company's IPO.

Will Doctolib launch in the UK?

Doctolib has not yet launched in the UK for a few reasons.

The UK healthcare system is different from other countries where Doctolib is already operating. In France and Germany, for example, healthcare is largely funded by the government, which makes it easier for Doctolib to negotiate contracts with healthcare providers. In the UK, healthcare is funded by a combination of private and public sources, which makes it more complex for Doctolib to operate.
The UK market is already crowded with other digital healthcare platforms. Companies like Babylon Health, Patient Access, and Zocdoc offer similar services to Doctolib, and they have already established a strong presence in the UK.
The UK government has not yet implemented a national electronic health record (EHR) system. An EHR would make it easier for Doctolib to share patient data between different healthcare providers, which is one of the main benefits of the platform.

However, Doctolib has said that they are still interested in launching in the UK, and they are currently in talks with healthcare providers and the government. It is possible that Doctolib could launch in the UK in the near future.

Here are some additional details about the reasons why Doctolib has not yet launched in the UK:

The UK healthcare system is more fragmented than other countries where Doctolib is operating. In France and Germany, there are national healthcare systems that cover most of the population. This makes it easier for Doctolib to negotiate contracts with healthcare providers, as they only need to do so with a few large organizations. In the UK, there are many different healthcare providers, each with their own contracts and procedures. This makes it more difficult for Doctolib to operate.
The UK government has not yet implemented a national EHR system. An EHR would make it easier for Doctolib to share patient data between different healthcare providers. This is one of the main benefits of the platform, as it allows patients to have a single view of their medical history. Without a national EHR system, Doctolib would have to rely on individual healthcare providers to share patient data, which could be difficult and time-consuming.

Despite these challenges, Doctolib has said that they are still interested in launching in the UK. They believe that the UK market is large and growing, and they are confident that they can overcome the challenges of operating in the UK healthcare system.

Doctolib IPO Valuation?

The valuation of a Doctolib IPO is difficult to predict, as it will depend on a number of factors, including the overall market conditions and the company's financial performance.

However, some analysts have estimated that the company could be valued at around $10 billion or more in an IPO.

Here are some factors that could affect the valuation of Doctolib in an IPO:

The company's growth rate. Doctolib has seen rapid growth in recent years, and this is likely to continue in the future. The company's growth rate will be a key factor in determining its valuation.
The company's financial performance. Doctolib has been profitable in recent years, and this is likely to continue in the future. The company's financial performance will also be a key factor in determining its valuation.
The competitive landscape. Doctolib is the leading digital healthcare platform in Europe, but there are a number of other companies that are vying for market share. The competitive landscape will also be a factor in determining the company's valuation.
The overall market conditions. The IPO market is cyclical, and it is possible that the market conditions will not be favorable for an IPO in 2024. The overall market conditions will also be a factor in determining the company's valuation.

Overall, the valuation of a Doctolib IPO is difficult to predict. However, if the market conditions are favorable and the company continues to grow, it is possible that the company could be valued at around $10 billion or more in an IPO.